공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

대장균 감염증 : 파이프라인 리뷰

Escherichia coli Infections (Infectious Disease) - Drugs in Development, 2021

리서치사 Global Markets Direct
발행일 2021년 09월 상품 코드 253652
페이지 정보 영문 212 Pages
가격
US $ 2,000 ₩ 2,395,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,790,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,185,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


대장균 감염증 : 파이프라인 리뷰 Escherichia coli Infections (Infectious Disease) - Drugs in Development, 2021
발행일 : 2021년 09월 페이지 정보 : 영문 212 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

대장균은 일반적으로 건강한 사람·동물의 장내에 살아 있습니다. 대장균 감염증은 사람·동물의 분변에 접촉하거나 분변에 오염된 물이나 음식을 섭취할 경우 발생합니다. 설사(경도의 수양성에서 중증의 출혈성까지), 복부 경련, 복통·복부압통, 오심·구토 등의 증상을 볼 수 있습니다. 소인으로 연령, 면역계 저하, 특정 음식(가열이 불충분한 햄버거, 저온 살균되지 않은 우유, 사과 주스·사이다, 생유로부터 만들어진 소프트 치즈 등)을 들 수 있습니다. 치료에는 항생물질, 건강한 생활 스타일 등이 포함됩니다.

대장균 감염증(Escherichia coli Infections) 치료제 개발 상황에 대해 조사 분석했으며, 파이프라인 제품 개요, 임상시험 단계별 제품 개요, 주요 기업 개요, 약제 개요, 파이프라인 제품의 최신 동향, 최신 뉴스와 프레스 릴리스 등의 정보를 전해드립니다.

목차

서론

대장균 감염증 개요

치료제 개발

  • 파이프라인 제품 : 개요
  • 기업별 파이프라인
  • 대학/연구기관에서 개발된 파이프라인
  • 기업에서 개발중인 제품
  • 대학/연구기관에서 개발중인 제품

치료제 평가

  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

치료제 개발 참여 기업

  • Abgentis Ltd
  • Adenium Biotech ApS
  • AstraZeneca Plc
  • Atterx Biotherapeutics Inc
  • AvidBiotics Corp
  • Cellceutix Corp
  • ContraFect Corp
  • Debiopharm International SA
  • Emergent BioSolutions Inc
  • F. Hoffmann-La Roche Ltd
  • GangaGen Inc
  • Hsiri Therapeutics LLC
  • ImmunoClin Corp
  • Immuron Ltd
  • Johnson & Johnson
  • Kyorin Pharmaceutical Co Ltd
  • Melinta Therapeutics Inc
  • Merck & Co Inc
  • Microbiotix Inc
  • Nabriva Therapeutics AG
  • Navigen Inc
  • Nosopharm SAS
  • Novabiotics Ltd
  • Paratek Pharmaceuticals Inc
  • Pherecydes Pharma SA
  • Phico Therapeutics Ltd
  • Recce Ltd
  • Sealife PHARMA GMBH
  • Soligenix Inc
  • Syntiron LLC
  • Tetraphase Pharmaceuticals Inc

약제 개요

휴지 상태인 프로젝트

개발이 중지된 제품

제품 개발 마일스톤

  • 최신 뉴스와 프레스 릴리스

부록

도표

LSH 17.07.24

List of Tables

List of Tables

  • Number of Products under Development for Escherichia coli Infections, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Companies, 2021 (Contd..1)
  • Number of Products under Development by Companies, 2021 (Contd..2)
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Companies, 2021 (Contd..1)
  • Products under Development by Companies, 2021 (Contd..2)
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Escherichia coli Infections - Pipeline by ABAC Therapeutics SA, 2021
  • Escherichia coli Infections - Pipeline by Affilogic SAS, 2021
  • Escherichia coli Infections - Pipeline by Alterity Therapeutics Ltd, 2021
  • Escherichia coli Infections - Pipeline by Armata Pharmaceuticals Inc, 2021
  • Escherichia coli Infections - Pipeline by AstraZeneca Plc, 2021
  • Escherichia coli Infections - Pipeline by Atterx Biotherapeutics Inc, 2021
  • Escherichia coli Infections - Pipeline by BB100 LLC, 2021
  • Escherichia coli Infections - Pipeline by Biomendics LLC, 2021
  • Escherichia coli Infections - Pipeline by Bugworks Research India Pvt Ltd, 2021
  • Escherichia coli Infections - Pipeline by ContraFect Corp, 2021
  • Escherichia coli Infections - Pipeline by Dong-A ST Co Ltd, 2021
  • Escherichia coli Infections - Pipeline by Eligo Bioscience SA, 2021
  • Escherichia coli Infections - Pipeline by EnBiotix Inc, 2021
  • Escherichia coli Infections - Pipeline by EveliQure Biotechnologies GmbH, 2021
  • Escherichia coli Infections - Pipeline by F. Hoffmann-La Roche Ltd, 2021
  • Escherichia coli Infections - Pipeline by Forge Therapeutics Inc, 2021
  • Escherichia coli Infections - Pipeline by GlyProVac ApS, 2021
  • Escherichia coli Infections - Pipeline by Johnson & Johnson, 2021
  • Escherichia coli Infections - Pipeline by Linnaeus Bioscience Inc, 2021
  • Escherichia coli Infections - Pipeline by Meiji Seika Pharma Co Ltd, 2021
  • Escherichia coli Infections - Pipeline by Melinta Therapeutics Inc, 2021
  • Escherichia coli Infections - Pipeline by Merck & Co Inc, 2021
  • Escherichia coli Infections - Pipeline by Microbiotix Inc, 2021
  • Escherichia coli Infections - Pipeline by Navigen Inc, 2021
  • Escherichia coli Infections - Pipeline by Neoculi Pty Ltd, 2021
  • Escherichia coli Infections - Pipeline by Northern Antibiotics Oy, 2021
  • Escherichia coli Infections - Pipeline by Nosopharm SAS, 2021
  • Escherichia coli Infections - Pipeline by Novabiotics Ltd, 2021
  • Escherichia coli Infections - Pipeline by Ostrich Pharma USA Inc, 2021
  • Escherichia coli Infections - Pipeline by Oxford Drug Design Ltd, 2021
  • Escherichia coli Infections - Pipeline by Paratek Pharmaceuticals Inc, 2021
  • Escherichia coli Infections - Pipeline by Pedanius Therapeutics Ltd, 2021
  • Escherichia coli Infections - Pipeline by PGTx Ltd, 2021
  • Escherichia coli Infections - Pipeline by Phico Therapeutics Ltd, 2021
  • Escherichia coli Infections - Pipeline by Planet Biotechnology Inc, 2021
  • Escherichia coli Infections - Pipeline by Procarta Biosystems Ltd, 2021
  • Escherichia coli Infections - Pipeline by Protein Potential LLC, 2021
  • Escherichia coli Infections - Pipeline by Pylum Biosciences Inc, 2021
  • Escherichia coli Infections - Pipeline by Recce Pharmaceuticals Ltd, 2021
  • Escherichia coli Infections - Pipeline by RemAb Therapeutics SL, 2021
  • Escherichia coli Infections - Pipeline by Shanghai Space Peptides Pharmaceutical Co Ltd, 2021
  • Escherichia coli Infections - Pipeline by Soligenix Inc, 2021
  • Escherichia coli Infections - Pipeline by Spero Therapeutics Inc, 2021
  • Escherichia coli Infections - Pipeline by Syntiron LLC, 2021
  • Escherichia coli Infections - Pipeline by VenatoRx Pharmaceuticals Inc, 2021
  • Escherichia coli Infections - Pipeline by Venus Medicine Research Centre, 2021
  • Escherichia coli Infections - Dormant Projects, 2021
  • Escherichia coli Infections - Dormant Projects, 2021 (Contd..1)
  • Escherichia coli Infections - Dormant Projects, 2021 (Contd..2)
  • Escherichia coli Infections - Dormant Projects, 2021 (Contd..3)
  • Escherichia coli Infections - Dormant Projects, 2021 (Contd..4)
  • Escherichia coli Infections - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Escherichia coli Infections, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Escherichia coli Infections - Drugs In Development, 2021, provides an overview of the Escherichia coli Infections (Infectious Disease) pipeline landscape.Escherichia coli (E. coli) bacteria normally live in the intestines of healthy people and animals. Escherichia coli infections are caused by coming into contact with the feces, or stool, of humans or animals or drink water or eat food that has been contaminated by feces. Symptoms include diarrhea, which may range from mild and watery to severe and bloody, abdominal cramping, pain or tenderness, nausea and vomiting. The predisposing factors include age, weakened immune systems and eating certain types of food like undercooked hamburger, unpasteurized milk, apple juice or cider and soft cheeses made from raw milk. Treatment includes antibiotics and healthy life style.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Escherichia coli Infections - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Escherichia coli Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Escherichia coli Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Escherichia coli Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 2, 2, 31 and 16 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 7 and 12 molecules, respectively.

Escherichia coli Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Escherichia coli Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Escherichia coli Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Escherichia coli Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Escherichia coli Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Escherichia coli Infections (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Escherichia coli Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Escherichia coli Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Escherichia coli Infections - Overview
  • Escherichia coli Infections - Therapeutics Development
  • Escherichia coli Infections - Therapeutics Assessment
  • Escherichia coli Infections - Companies Involved in Therapeutics Development
  • Escherichia coli Infections - Drug Profiles
  • Escherichia coli Infections - Dormant Projects
  • Escherichia coli Infections - Discontinued Products
  • Escherichia coli Infections - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q